

Samra Turajlic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1842902/publications.pdf>

Version: 2024-02-01

94
papers

12,797
citations

70961

41
h-index

45213

90
g-index

107
all docs

107
docs citations

107
times ranked

19940
citing authors

#	ARTICLE	IF	CITATIONS
1	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121.	13.9	1,786
2	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017, 545, 446-451.	13.7	1,287
3	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017, 171, 1259-1271.e11.	13.5	968
4	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1009-1021.	5.1	716
5	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. <i>Cell</i> , 2018, 173, 581-594.e12.	13.5	609
6	Metastasis as an evolutionary process. <i>Science</i> , 2016, 352, 169-175.	6.0	497
7	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021, 184, 596-614.e14.	13.5	485
8	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. <i>Cell</i> , 2018, 173, 595-610.e11.	13.5	472
9	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4.	7.7	448
10	Resolving genetic heterogeneity in cancer. <i>Nature Reviews Genetics</i> , 2019, 20, 404-416.	7.7	443
11	Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. <i>Cell</i> , 2018, 173, 611-623.e17.	13.5	398
12	<i>SF3B1</i> Mutations Are Associated with Alternative Splicing in Uveal Melanoma. <i>Cancer Discovery</i> , 2013, 3, 1122-1129.	7.7	358
13	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. <i>Immunity</i> , 2017, 46, 577-586.	6.6	323
14	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. <i>Cancer Discovery</i> , 2013, 3, 158-167.	7.7	300
15	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	13.7	221
16	Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. <i>Annals of Oncology</i> , 2017, 28, 377-385.	0.6	215
17	The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part A: Renal, Penile, and Testicular Tumours. <i>European Urology</i> , 2022, 82, 458-468.	0.9	212
18	Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. <i>Journal of Pathology</i> , 2013, 230, 261-269.	2.1	180

#	ARTICLE	IF	CITATIONS
19	Whole genome sequencing of matched primary and metastatic acral melanomas. <i>Genome Research</i> , 2012, 22, 196-207.	2.4	155
20	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
21	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
22	Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2016, 27, 1135-1137.	0.6	131
23	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	7.7	126
24	Kidney cancer: The next decade. <i>Journal of Experimental Medicine</i> , 2018, 215, 2477-2479.	4.2	125
25	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
26	BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling. <i>Science Signaling</i> , 2014, 7, ra30.	1.6	113
27	The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 835-838.	1.5	108
28	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	1.3	97
29	Tracking Cancer Evolution through the Disease Course. <i>Cancer Discovery</i> , 2021, 11, 916-932.	7.7	77
30	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17.	4.3	70
31	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. <i>Nature Medicine</i> , 2021, 27, 1362-1366.	15.2	70
32	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	5.7	66
33	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. <i>Nature Communications</i> , 2020, 11, 3800.	5.8	61
34	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. <i>Lancet</i> , The, 2022, 399, 905-907.	6.3	60
35	A whole-genome massively parallel sequencing analysis of <i>BRCA1</i> mutant oestrogen receptor-negative and -positive breast cancers. <i>Journal of Pathology</i> , 2012, 227, 29-41.	2.1	58
36	Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. <i>Annals of Oncology</i> , 2014, 25, 959-967.	0.6	53

#	ARTICLE	IF	CITATIONS
37	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	2.9	51
38	SnapShot: Renal Cell Carcinoma. <i>Cell</i> , 2015, 163, 1556-1556.e1.	13.5	50
39	Selection of metastasis competent subclones in the tumour interior. <i>Nature Ecology and Evolution</i> , 2021, 5, 1033-1045.	3.4	50
40	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. <i>Cancer Cell</i> , 2022, 40, 114-116.	7.7	50
41	Inferring mutational timing and reconstructing tumour evolutionary histories. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 264-275.	3.3	48
42	The status of tumor mutational burden and immunotherapy. <i>Nature Cancer</i> , 2022, 3, 652-656.	5.7	48
43	Genomic characterisation of acral melanoma cell lines. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 488-492.	1.5	46
44	Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 105-118.	1.4	45
45	An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 561-570.	1.0	43
46	Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study. <i>Cell</i> , 2020, 183, 4-10.	13.5	40
47	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. <i>Histopathology</i> , 2022, 81, 426-438.	1.6	39
48	How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. <i>Current Opinion in Urology</i> , 2015, 25, 358-366.	0.9	34
49	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 679-697.	3.7	33
50	Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 113-117.	2.0	31
51	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. <i>Nature Ecology and Evolution</i> , 2022, 6, 88-102.	3.4	30
52	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 177-189.	1.8	29
53	Implications of cancer evolution for drug development. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 441-442.	21.5	28
54	Tumour mutational burden: primary versus metastatic tissue creates systematic bias. <i>Immuno-Oncology Technology</i> , 2019, 4, 8-14.	0.2	26

#	ARTICLE	IF	CITATIONS
55	How we treat neurological toxicity from immune checkpoint inhibitors. <i>ESMO Open</i> , 2020, 4, e000540.	2.0	25
56	Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. <i>ESMO Open</i> , 2020, 5, e000585.	2.0	23
57	Immunotherapy use outside clinical trial populations: never say never?. <i>Annals of Oncology</i> , 2021, 32, 866-880.	0.6	22
58	First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. <i>Annals of Oncology</i> , 2018, 29, 542-543.	0.6	16
59	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
60	The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released. <i>Cancer Discovery</i> , 2017, 7, 796-798.	7.7	14
61	Evolution of Renal Cell Carcinoma. <i>European Urology Focus</i> , 2021, 7, 148-151.	1.6	14
62	SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay. <i>Wellcome Open Research</i> , 2021, 6, 9.	0.9	13
63	Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. <i>ESMO Open</i> , 2018, 3, e000317.	2.0	12
64	New survival standards for advanced melanoma. <i>British Journal of Cancer</i> , 2020, 122, 1275-1276.	2.9	12
65	Phase I/II RAF kinase inhibitors in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 739-749.	1.9	11
66	Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 250-255.	1.2	11
67	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. , 2021, 9, e002835.		11
68	SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay. <i>Wellcome Open Research</i> , 2021, 6, 9.	0.9	11
69	Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 195-203.	1.8	11
70	Generalized melanosis and melanuria in a patient with metastatic melanoma. <i>Clinical and Experimental Dermatology</i> , 2010, 35, e37-e39.	0.6	10
71	The Genetic Evolution of Metastasis. <i>Cancer Research</i> , 2022, 82, 1849-1857.	0.4	10
72	Identification of conserved evolutionary trajectories in tumors. <i>Bioinformatics</i> , 2020, 36, i427-i435.	1.8	9

#	ARTICLE	IF	CITATIONS
73	Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. <i>Human Molecular Genetics</i> , 2022, 31, 3001-3011.	1.4	9
74	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877742.	1.4	7
75	Immunotherapy for Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 789-790.	13.9	7
76	Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 338-341.	0.6	5
77	A protocol for representative sampling of solid tumors to improve the accuracy of sequencing results. <i>STAR Protocols</i> , 2021, 2, 100624.	0.5	5
78	Tracking tumour evolution through liquid biopsy. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 565-566.	12.5	4
79	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 167-175.	0.9	4
80	ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4583-TPS4583.	0.8	4
81	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. <i>NAR Cancer</i> , 2022, 4, .	1.6	4
82	Relapse models for clear cell renal carcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e376-e378.	5.1	3
83	PTU-009's Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea. , 2018, , .		2
84	Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma. <i>Annals of Oncology</i> , 2019, 30, 355-357.	0.6	2
85	Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. <i>European Journal of Cancer</i> , 2021, 156, 187-189.	1.3	2
86	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
87	Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products. <i>Cancer Research</i> , 2020, 80, 875-875.	0.4	2
88	Systemic treatment of advanced papillary renal cell carcinoma: Where next?. <i>European Journal of Cancer</i> , 2016, 69, 223-225.	1.3	1
89	PWE-025's Microscopic colonic inflammation in immune check point inhibitor-induced diarrhoea/colitis. , 2018, , .		1
90	Standing on the shoulders of giants. <i>Nature Medicine</i> , 2019, 25, 357-357.	15.2	1

#	ARTICLE	IF	CITATIONS
91	Metastasis and organotropism: A look through the lens of large-scale clinical sequencing data. Cancer Cell, 2022, 40, 134-135.	7.7	1
92	Predicting cancer evolution for patient benefit: Renal cell carcinoma paradigm. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188759.	3.3	1
93	Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTMmanufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use. , 2020, , .		0
94	Abstract PO-091: CAPTURE: Cancer and COVID-19 antiviral immune monitoring study. , 2020, , .		0